论文部分内容阅读
目的:研究谷胱甘肽复方注射液(CGII)对猪血清所致免疫性肝纤维化大鼠肝组织中血小板衍生生长因子-B(PDGF-B)及转化生长因子-β1(TGF-β1)mRNA和蛋白表达的影响。方法:建立猪血清诱导免疫性肝纤维化模型成功后,药物治疗6周。实时荧光定量PCR及免疫印迹法检测大鼠肝组织中PDGF-B和TGF-β1 mRNA以及蛋白的表达。结果:在猪血清诱导大鼠肝纤维化模型,CGII(5.4,10.8 mg.kg-1,im)能明显降低肝组织PDGF-B及TGF-β1 mRNA的表达;CGII(2.7,5.4,10.8 mg.kg-1,im)能明显降低肝组织PDGF-B及TGF-β1蛋白的表达。结论:CGII抗大鼠免疫性肝纤维化的作用机制可能与其下调肝组织PDGF-B和TGF-β1 mRNA及蛋白水平的表达有关。
Objective: To investigate the effects of CGII on the expression of platelet-derived growth factor-B (PDGF-B) and transforming growth factor-β1 (TGF-β1) in the liver of immunized hepatic fibrosis rats induced by swine serum. Effects of mRNA and protein expression. Methods: After the successful establishment of pig serum induced immune hepatic fibrosis model, the drug treatment for 6 weeks. Real-time fluorescence quantitative PCR and Western blotting were used to detect the expression of PDGF-B and TGF-β1 mRNA and protein in rat liver tissue. Results: CGII (5.4, 10.8 mg.kg-1, im) significantly reduced the expression of PDGF-B and TGF-β1 mRNA in the rat liver fibrosis model induced by porcine serum; CGII (2.7, 5.4 and 10.8 mg kg-1, im) can significantly reduce the expression of PDGF-B and TGF-β1 in liver tissue. CONCLUSION: The mechanism of CGII on immune-induced hepatic fibrosis in rats may be related to the down-regulation of the expression of PDGF-B and TGF-β1 mRNA and protein in liver tissue.